Victoria, BC, May 31, 2022--Eupraxia Pharmaceuticals Inc. (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the first quarter ended March 31, 2022.

Victoria, BC, September 30, 2021--Eupraxia Pharmaceuticals Inc. (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, announced an update for its lead osteoarthritis (OA) drug candidate EP-104IAR.

Victoria, BC, July 29, 2021--Eupraxia Pharmaceuticals Inc. (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, announced the authorization of its Clinical Trial Application ("CTA") by the Danish Medicines Agency ("DKMA").